Study shows safety, effectiveness for non-invasive wet AMD treatment

Article

Non-naïve wet AMD patients continued to receive the benefit of a 25% mean reduction in anti-VEGF injections over 2 years.

Newark, CA-Two-year results of a therapy for wet age-related macular degeneration show a favorable safety profile and reduced frequency of anti-vascular endothelial growth factor (VEGF) injections in the eye.

Oraya Therapeutics, Inc.’s Stereotactic Radiotherapy uses low-energy, highly targeted X-rays for the treatment of wet AMD. Intended as a one-time procedure, it is non-invasive, rapid, comfortable for the patient, and easy for a trained operator to perform. The total procedure time is typically less than 20 minutes. The IRay radiotherapy system’s delivery approach, targeting algorithm, eye stabilization, and tracking methods are proprietary.

The INTREPID study’s broadly inclusive cohort of non-naïve wet AMD patients continued to receive the benefit of a 25% mean reduction in anti-VEGF injections over 2 years. Patients identified in the first year as ideal response candidates maintained a 45% mean reduction in anti-VEGF injections through the 2-year visit, with superior vision to the non-treated group. In addition, the overall safety profile was positive, with 1% of treated patients showing evidence of micro-vascular abnormalities due to radiation that could affect vision outcomes.

“A treatment that offers the prospect of fewer injections will be welcomed by clinicians and patients alike, said Timothy L. Jackson, PhD, FRCOphth, King’s College Hospital, London, lead investigator for the INTREPID trial. “Importantly, if we select the right patients, vision appears to be better than with anti-VEGF monotherapy. The safety at two years is also encouraging, in that most micro-vascular changes were located away from the fovea, and so did not have an impact on vision.”

Related Videos
A. Philip Aitsebaomo, O.D., Ph.D. outlines his talk on treating patients with prosthetic eyes
Charissa Lee, OD, MBA, FAAO, talks DEI in leadership roles in optometry
Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO
Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO
Mandy Sallach of Johnson & Johnson speaks on initiatives to combat pediatric myopia
Vittorio Mena, OD, MS
Spencer Johnson, OD, FAAO, overviews his talk on laser procedures at Optometry's Meeting
GWCO past-president and treasurer outline the 2024 Congress event in October
Dr Clark Chang overviews how to fit wavefront guided contact lenses at Optometry's Meeting
Ruth Shoge, OD, MPH, FAAO, details a lecture she gave on ACES at Optometry's Meeting
© 2024 MJH Life Sciences

All rights reserved.